Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Archives of ophthalmology. 2009 Apr;127(4):533.40.
Gorin MB. Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics. Molecular aspects of medicine. 2012 Aug;33(4):467.86.
Campochiaro PA. Gene transfer for neovascular age-related macular degeneration. Human gene therapy. 2011 May;22(5):523.9.
He S, Li X, Chan N, Hinton DR. Review: Epigenetic mechanisms in ocular disease. Molecular vision. 2013 Jan;19:665.74.
Buentello-Volante B, Rodriguez-Ruiz G, Miranda-Duarte A, Pompa-Mera EN, Graue- Wiechers F, Bekker-Mendez C, et al. Susceptibility to advanced age-related macular degeneration and alleles of complement factor H, complement factor B, complement component 2, complement component 3, and age-related maculopathy susceptibility 2 genes in a Mexican population. Molecular vision. 2012 Jan;18(October):2518.25.
Awh CC, Lane A-M, Hawken S, Zanke B, Kim IK. CFH and ARMS2 Genetic Polymorphisms Predict Response to Antioxidants and Zinc in Patients with Agerelated Macular Degeneration. Ophthalmology. 2013 Aug 20;
Wang VM, Rosen RB, Meyerle CB, Kurup SK, Ardeljan D, Agron E, et al. Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration. Molecular vision. 2012 Jan;18:2578.85.
McKibbin M, Ali M, Bansal S, Baxter PD, West K, Williams G, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. The British journal of ophthalmology. 2012 Feb;96(2):208.12.
Abedi F, Wickremasinghe S, Richardson AJ, Makalic E, Schmidt DF, Sandhu SS, et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology. 2013 Jan;120(1):115.21.
Mao Y, Kiss S, Boyer JL, Hackett NR, Qiu J, Carbone A, et al. Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab. Human gene therapy. 2011 Dec;22(12):1525.35.
Balaggan KS, Ali RR. Ocular gene delivery using lentiviral vectors. Gene therapy. 2012 Feb;19(2):145.53.
Maclachlan TK, Lukason M, Collins M, Munger R, Isenberger E, Rogers C, et al. Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Molecular therapy : the journal of the American Society of Gene Therapy. 2011 Feb;19(2):326.34.
Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Human gene therapy. 2006 Feb;17(2):167.76.
Guzman-Aranguez A, Loma P, Pintor J. Small interfering RNAs (siRNAs) as a promising tool for ocular therapy. British journal of pharmacology. 2013 Aug 13;
Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus KJ, et al. Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye (London, England). 2012 Aug;26(8):1099.105.
Kaiser PK, Symons RCA, Shah SM, Quinlan EJ, Tabandeh H, Do D V, et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. American journal of ophthalmology. 2010 Jul;150(1):33.39.e2.
Wang S, Koster KM, He Y, Zhou Q. miRNAs as potential therapeutic targets for agerelated macular degeneration. Future medicinal chemistry. 2012 Mar;4(3):277.87.
Katoh M. Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review). International journal of molecular medicine. 2013 Oct;32(4):763.7.
Kutty RK, Nagineni CN, Samuel W, Vijayasarathy C, Jaworski C, Duncan T, et al. Differential regulation of microRNA-146a and microRNA-146b-5p in human retinal pigment epithelial cells by interleukin-1β, tumor necrosis factor-α, and interferon-γ. Molecular vision. 2013 Jan;19:737.50.
Lukiw WJ, Surjyadipta B, Dua P, Alexandrov PN. Common micro RNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer's disease (AD) and in age-related macular degeneration (AMD). International journal of biochemistry and molecular biology. 2012 Jan;3(1):105.16.
